Pilot Study to Evaluate Serum Soluble Mesothelin-Related Peptide (SMRP) as Marker for Clinical Monitoring of Pleural Mesothelioma (PM): Correlation with Modified RECIST Score

A soluble mesothelin-related peptide (SMRP) is the only FDA-approved biomarker for diagnosis of pleural mesothelioma (PM) and the most used for monitoring treatment. Radiological assessment of PM, based on modified RECIST (mRECIST) criteria, is challenging. This pilot study was designed to evaluate...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Federica Grosso, Matilde Mannucci, Francesca Ugo, Paola Ferro, Maurizio Cassinari, Antonella Vigani, Antonina Maria De Angelis, Sara Delfanti, Michela Lia, Roberto Guaschino, Stefano Barbero, Silvio Roncella, Ugo Giannoni, Marinella Bertolotti, Maria Pia Pistillo, Vincenzo Fontana
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	mesothelioma mesothelin serum biomarkers modified RECIST longitudinal study Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/28405c6350474f358c3d863dfe112cdc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Pilot Study to Evaluate Serum Soluble Mesothelin-Related Peptide (SMRP) as Marker for Clinical Monitoring of Pleural Mesothelioma (PM): Correlation with Modified RECIST Score

Ejemplares similares